Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Sanofi

Benzinga Before The Bell: Gun Safety Bill. Bill Gates North Dakota Outrage, Sanofi-GSK's Covid-19 Vaccine's Omicron Efficacy And Other Top Financial Stories Friday, June 24

Reuters

Benzinga

Sanofi-GSK's Beta-Containing COVID-19 Vaccine Shows Efficacy Against Omicron

Sanofi SA (NASDAQ:SNY) and GSK plc (NYSE:GSK) have announced positive data from their vaccine trial of adjuvanted bivalent D614 and Beta (B.1.351) vaccine candidate. "Sanofi-GSK's vaccine is the first candidate to demonstrate efficacy in a placebo-controlled trial in an environment of high Omicron variant circulation," Sanofi said in a statement. The bivalent vaccine targets the…

Benzinga

Sanofi, GSK variant-specific COVID shot found effective against Omicron

(Fixes typographical error in media identifier)

Reuters

From analysis to the latest developments in health,
read the most diverse news in one place.

Peer review: Can this critical step in the publication of science research be kinder?

Democracy has been called the least worst system of government. Peer review is the least worst system for assessing the merit of scientific work.

The Conversation

The hard road for the Novavax vaccine

Novavax now in financial trouble after missing peak vaccinations

Salon

California wants to slash insulin prices by becoming a drugmaker. Can it succeed?

SACRAMENTO, Calif. — California is diving into the prescription drug business, attempting to achieve what no other state has done: produce its own brand of generic insulin and sell it at below-market prices to people with diabetes like Sabrina Caudillo.

Tribune News Service

Drugmakers urged to give poorer nations access to more antibiotics

Antifungals also needed, says study, as drug resistance has increased faster than expected, particularly in sub-Saharan Africa

The Guardian - UK

Read news from The Economist, FT, and more,
with one subscription

U.S. FDA Approves Regeneron And Sanofi's Lead Drug For Skin Inflammation In Children

The U.S.

Benzinga

Regeneron Pharmaceuticals Dives On $1.1 Billion Deal To Rival Merck In Cancer

Regeneron stock tumbled Thursday after the company announced a deal to acquire the international rights to Sanofi-partnered cancer drug Libtayo.

Investors Business Daily

Oil Stocks Lead Charge Of Breakouts And Buy Zones In New Uptrend

With a new uptrend underway, oil stocks like TotalEnergies and tech stocks like Synopsys set the stage for new breakouts.

Investors Business Daily

Novavax missed its global moonshot but is angling to win over mRNA defectors

Novavax hitched its wagon to the global coronavirus pandemic. Before most Americans truly grasped the scope of the danger, the small Maryland biotech startup had secured $1.6 billion in U.S. funding for its COVID-19 vaccine. Its moonshot goal: delivering 2 billion shots to the world by mid-2021.

Tribune News Service

FDA Approves Regeneron and Sanofi's Dupixent (dupilumab) For Eosinophilic Esophagitis (EoE) Ahead of Schedule

The U.S. Food and Drug Administration (FDA) has approved Regeneron Pharmaceuticals, Inc.

Benzinga

Sanofi To Pay €400K As Compensation For Epilepsy Drug-Related Side Effects

A French court has ordered Sanofi SA (NASDAQ: SNY) to pay more than €400,000 in damages to a French family whose child had autism caused by its epilepsy drug Valproate.

Benzinga

Why Tech Leader Regeneron Shouldn't Sweat Its AbbVie Rival — For Now

AbbVie could soon pressure Regeneron in eczema treatment, an analyst said Friday as Regeneron stock hit a ceiling at its 200-day line.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Is Dario (DRIO) Health Eating Teladoc's (TDOC) Lunch? Q1 Earnings on Tap Thursday After Meeting with Sanofi (SNY)

Teladoc (NYSE: TDOC) stock recently cratered to a new 52 week low following it’s Q1 report. Some of it’s shortfall was attributed by management to longer sales cycles in the insurer and employer space in addition to competitive concerns.

Benzinga

Why Kymera Therapeutics Shares Are Falling Today

In its Q1 earnings release, Kymera Therapeutics Inc (NASDAQ:KYMR) announced the selection of the equivalent of 100 mg, in the fed state, as the dose for the Phase 1 patient cohort (Part C). The cohort is expected to enroll up to 20 patients with hidradenitis suppurativa (HS) and atopic dermatitis (AD). In…

Investors Business Daily

Stock Market Volatile; Apple, Facebook, Amazon Are Key Earnings, Tesla CEO Elon Musk Buys Twitter: Weekly Review

A market rally attempt is underway, but the major indexes lost ground. Apple and Facebook led key earnings. Elon Musk will buy Twitter.

Benzinga

Dupixent, Consumer Healthcare Lifts Sanofi's Q1 Earnings, Backs FY22 Guidance

Sanofi SA (NASDAQ:SNY) posted a net profit of €2 billion for Q1 FY22, up from €1.57 billion a year ago. Sales reached €9.67 billion, up from €8.59 billion in Q1 FY21. Eczema drug, Dupixent, and consumer healthcare drove the growth. Dupixent alone grew by 45.7% to €1.6 billion, driving Sanofi's specialty care…

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Sanofi Scores A Big Beat As Dupixent Snags The Spotlight, Again

Sanofi stock rose Thursday on strong revenue growth for the company's allergic conditions treatment, Dupixent.

Benzinga

Psyched: Big Pharma's Sanofi Enters Psychedelics Space, DNA From 80 Psilocybe Mushrooms Published Online, Maine Psychedelics Bill Shelved

Benzinga’s first-ever Psychedelics Capital Conference was a colossal success. Over 600 investors, policymakers, industry executives and thought leaders gathered at the Fontainebleau Hotel in Miami Beach for a full day of networking and education.

Benzinga

Big Pharma's Sanofi Enters Licencing Agreement With Private Psychedelics Company Terran

Terran Biosciences is slowly but surely finding its place in the psychedelics industry.

Benzinga

How To Attend Sanofi Q1 2022 Earnings Conference Call

Sanofi (NASDAQ:SNY) will host a conference call at 08:30 AM ET on April 28, 2022, to discuss Q1 2022 earnings results.

Benzinga

Sanofi's Rilzabrutinib Data In Autoimmune Blood Disorder Published In New England Journal of Medicine

Results from the Phase 1/2 dose-finding study evaluating Sanofi SA's (NASDAQ:SNY) rilzabrutinib in adults with heavily pre-treated immune thrombocytopenia (ITP) were published in the New England Journal of Medicine. Results demonstrate that rilzabrutinib treatment led to a rapid and durable increase in platelet count and supports an acceptable safety profile. Sanofi is investigating…

Tribune News Service

Why Black and Hispanic seniors are left with a less powerful flu vaccine

At Whitman-Walker Health, Dr. David Fessler and his staff administer high-dose influenza vaccine to all HIV-positive and senior patients. Although the vaccine is roughly three times as expensive as standard flu vaccine, it seems to do a better job at protecting those with weakened immune systems — a major focus…

Benzinga

Sanofi To List Drug Ingredient Spin-Off EUROAPI On Euronext Paris in May

Sanofi SA (NASDAQ: SNY) plans to list its drug ingredients subsidiary EUROAPI on May 6, saying the business is set to grow and improve its profitability as a separate business.

1 … 7 8 9 10

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations